|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0010346,
umls-concept:C0036043,
umls-concept:C0087111,
umls-concept:C0443252,
umls-concept:C0666743,
umls-concept:C0871261,
umls-concept:C1096776,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2698872,
umls-concept:C2911692
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2008-9-11
|
|
pubmed:abstractText |
Efficacy of infliximab in Crohn's disease (CD) showed by randomized controlled trials must be confirmed in clinical practice. We aimed to evaluate efficacy and safety of infliximab in CD patients of the Madrid area, looking for clinical predictors of response.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0210-5705
|
|
pubmed:author |
pubmed-author:AbreuLuisL,
pubmed-author:BermejoFernandoF,
pubmed-author:CalvoMartaM,
pubmed-author:CarnerosJosé AntonioJA,
pubmed-author:CasisBegoñaB,
pubmed-author:GisbertJavier PJP,
pubmed-author:González-LamaYagoY,
pubmed-author:Group for the Study of Inflammatory Bowel Diseases from Madrid (ENICMAD),
pubmed-author:HuertaAlaínA,
pubmed-author:López-PalaciosNataliaN,
pubmed-author:López-San RománAntonioA,
pubmed-author:LópezPilarP,
pubmed-author:Marín-JiménezIgnacioI,
pubmed-author:Martínez-MontielPilarP,
pubmed-author:Martínez-SilvaFranciscaF,
pubmed-author:MatéJoséJ,
pubmed-author:MenchénLuisL,
pubmed-author:MendozaJuan LuisJL,
pubmed-author:MilicuaJosé MaríaJM,
pubmed-author:Pérez-CalleJosé LázaroJL,
pubmed-author:SánchezFernandoF,
pubmed-author:TaxoneraCarlosC,
pubmed-author:VeraIsabelI
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
31
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
421-6
|
|
pubmed:meshHeading |
pubmed-meshheading:18783686-Adolescent,
pubmed-meshheading:18783686-Adult,
pubmed-meshheading:18783686-Aged,
pubmed-meshheading:18783686-Aged, 80 and over,
pubmed-meshheading:18783686-Anti-Inflammatory Agents,
pubmed-meshheading:18783686-Antibodies, Monoclonal,
pubmed-meshheading:18783686-Crohn Disease,
pubmed-meshheading:18783686-Female,
pubmed-meshheading:18783686-Humans,
pubmed-meshheading:18783686-Male,
pubmed-meshheading:18783686-Middle Aged,
pubmed-meshheading:18783686-Retrospective Studies,
pubmed-meshheading:18783686-Time Factors,
pubmed-meshheading:18783686-Young Adult
|
|
pubmed:articleTitle |
Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response.
|
|
pubmed:affiliation |
La Princesa University Hospital (Universidad Autónoma) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd II).
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
